About Diamedica
DiaMedica is a biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for diabetes and other major, medically-unmet diseases. DiaMedica’s lead compound, DM-199,
is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes.
In a Type 1 diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin producing beta cells, resulting in significant improvement in glucose control.
DiaMedica is also developing a novel monoclonal antibody, DM-204, as a treatment for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in significant improvement in blood glucose control and HbA1c levels and also significant decreases in blood pressure and serum cholesterol.
DiaMedica’s DM-199 and DM-204 were both named Windhover’s “2011 Top 10 Cardiovascular/ Metabolic Projects to Watch”. DiaMedica is a publicly traded company, listed on the TSX Venture Exchange under the symbol DMA.
Recent Headlines
May 9th 2012
DiaMedica Receives $3,166,800 Through Warrant Incentive Program
WINNIPEG, Manitoba – May 8, 2012 – DiaMedica (TSX-V:DMA) is very pleased to announce that it has received proceeds of $3,166,800 pursuant to the early exercise warrant incentive program (the “Program”) previously disclosed in its press release dated April 2, 2012 relating to the early exercise of the warrants that were previously issued...
>> Read More...Apr 2nd 2012
DiaMedica Receives Conditional Approval to Accelerate Warrant Exercise
WINNIPEG, Manitoba – April 2, 2012 – DiaMedica Inc. (TSX-V:DMA) is pleased to announce that it has received conditional approval from the the TSX Venture Exchange (the “TSXV”) for an incentive program (the “Incentive Program”) to encourage the early exercise of the 3,105,000 warrants that were previously issued in connection with DiaMedica...
>> Read More...Mar 22nd 2012
DiaMedica Provides Update on DM-199 & DM-204 and Appoints Mr. Ed Rady as Senior Consultant, Licensing & Partnering
Winnipeg, MB, March 22, 2012
- DM-199 & DM-204 were both selected on December 1, 2011 as Windhover’s “2011 Top 10 Cardiovascular/ Metabolic Projects to Watch”
- Appointing of Mr. Edward Rady as Senior Consultant, Licensing & Partnering
- Started preliminary discussions with major pharmaceutical companies